News

PCAS and Nanosyn have signed a joint-venture agreement to operate PCAS-Nanosyn, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California. The newly created company, PCAS-Nanosyn will

Avanir has reported that the investigational drug Zenvia (dextromethorphan/quinidine) has met its primary efficacy endpoint in the confirmatory phase III STAR trial, for the treatment of pseudobulbar affect

NuPathe has reported the top-line results from the pivotal phase III clinical trial of Zelrix, a novel transdermal patch in clinical development, for the treatment of acute migraine.

Omeros has reported the results from the phase 1/phase 2 clinical trial of OMS302, an ophthalmologic PharmacoSurgery product candidate. OMS302 is a combination of an anti-inflammatory agent and

Javelin Pharmaceuticals (Javelin) has provided top line results from a phase III randomized, multicenter, double-blind, 1:1 placebo-controlled study of Ereska (intranasal ketamine 30mg). The study assessed the safety

Essentialis plans to file a Special Protocol Assessment (SPA) with FDA for the pivotal study to support the NDA filing for its drug, DCCR. The drug is intended

Corcept Therapeutics, a pharmaceutical company engaged in the development of drugs for the treatment of severe metabolic and psychiatric disorders, has reported financial results for the second quarter

Cardium Therapeutics has reported its financial results for the second quarter ended June 30, 2009. For this period, the company reported a loss from operations of $2.3m, as

Repros Therapeutics has received notification of a class action complaint against it, on 7 August 2009 and certain of its officers and directors, on behalf of shareholders who